As a gram-negative and microaerophilic bacterium, Helicobacter pylori (HP) is the main cause of chronic gastritis. Therefore, considering the high prevalence of HP infection worldwide, as well as the increasing prevalence of metabolic disorders, the present study aimed to investigate the relationship between HP infection eradication and metabolic profile.

This prospective case-control study was performed on patients with HP infection whom referred to 8 medical centers in 3 countries (Iran, Egypt, and Vietnam) in 2020 – 2021. Then the prevalence of any comorbidity compared between those with successful HP eradication (group A) and subjects who failed to eradicate (group B).

Overall 199 patients included (46.7% male, average age 44.6 y, range 14-93). Racially 86.9% of participants were Caucasian. 177 cases (88.9%) diagnosed as non-ulcer dyspepsia (NUD). The most prevalent therapeutic regimens include high dose amoxicillin dual therapy (44.7%) and clarithromycin base (27.1%). After treatment, 164 cases (824.%) achieved successful HP eradication and allocated as group A. Rest of participant who failed eradication, assigned as group B (35 cases). Baseline demographic characters of 2 groups were equal. There was higher prevalence of comorbidities such as hypertension and hyperlipidemia among resistant cases who fail to achieve HP eradication (P=0.02). This issue means higher probability of successful HP eradication among those without comorbidity (86.8% versus 68%, P= 0.0031).

HP eradication among subjects with several comorbidities mandates eradication protocol intensification to avoid treatment failure.